Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + Chemotherapy + SRS for NSCLC Brain Metastases
NCT07535463Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Recommended Phase 2 Dose at 21 days and Intracranial Progression-Free Survival at 3 months. Started Apr 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07535463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535463.